Practical
insights
for scoring
HER2

Discussing challenges and
recommendations for HER2
IHC assessment with the Pathology
Faculty.

educational cources hero image

FEATURED

Unusual staining pattern: Basolateral staining in micropapillary carcinoma

In this article, Dr. Jaffer, MD, details the interpretation of biomarker testing in invasive micropapillary carcinomas.

by Shabnam Jaffer, MD

Decalcified bone specimen: Processing procedures

In this article, Dr. Wei, MD, PhD, discusses the use of bone specimens as samples for HER2 IHC in metastatic breast cancer.

by Shi Wei, MD, PhD

Impact of pre-analytic variables on HER2 IHC results

In this article, Dr. Khoury, MD, reviews several different pre-analytic variables and their impact on HER2 IHC assessment.

by Thaer Khoury, MD

Recommendations for testing of cytology specimens

In this article, Dr. Bui, MD, PhD, discusses the advantages and disadvantages of using cytology samples for HER2 IHC testing in breast cancer.

by Marylin Bui, MD, PhD

HER2, human epidermal growth factor receptor 2; IHC, immunohistochemistry.

Explore Clinical Case Reviews

View all

In these clinical case reviews, the Pathology Faculty share their experience with their most complex cases and highlight practices that improve consistency in HER2 IHC scoring.

FEATURED CASE

The importance of reporting discrete HER2 IHC scores

In this case, the patient presented with primary breast cancer classified as HER2-negative.

by Marilyn Bui, MD, PhD

Assessing HER2 IHC with cytoplasmic staining

In this case, the HER2 IHC on a segmental mastectomy specimen from a primary invasive ductal carcinoma showed an unusual cytoplasmic staining pattern.

by Savitri Krishnamurthy, MD

Assessing HER2 IHC with edge artifacts

In this case, the HER2 IHC of a core needle biopsy specimen from an invasive breast carcinoma showed signs of edge artifact.

by Gary Tozbikian, MD

Interpreting HER2 IHC with an extensive in situ component

In this case, there was an extensive in situ component present along with the invasive carcinoma, and HER2 IHC scores were discordant between the two.

by Hannah Wen, MD, PhD

Breast Cancer Resources

Breast Cancer Resources

Discover a range of peer-led learning videos designed to help you evolve HER2 assessment in breast cancer with the changing clinical practice.

Explore Resources